Kornimate/medical-research-clean huggingface dataset:
surface neuromuscular electrical stimulation in the treatment of chronic venous leg ulcers

Conditions: Chronic Venous Disease

Summary: this study aims to determine if the use of surface neuromuscular electrical stimulation, applied to various motor points on the lower limb to elicit muscle contraction when combined with compression bandaging accelerates the rate of venous leg ulcer healing.

with an increasingly ageing population the incidence of venous ulceration is likely to rise. the negative impact of leg ulceration on patients' quality of life and on healthcare costs is well recognised. increased prevalence combined with poor reported healing rates and high incidence of ulcer recurrence makes the development of a new treatment which could accelerate healing rates beyond that currently achieved using compression bandaging most desirable. surface neuromuscular electrical stimulation in combination with compression bandaging may provide such a treatment. surface neuromuscular electrical stimulation (snmes) is the application of an electrical stimulus to motor points in the body using electrodes placed on the surface of the skin to elicit a muscular contraction. it has been shown that snmes of the calf muscles, when used in conjunction with compression therapy, provides improved venous flow velocities over compression therapy alone. furthermore, the week-long effect of snmes and compression therapy on healthy participants was found to be well tolerated by all participants and resulted in increases in stimulated venous flow and muscle strength. a combined snmes and compression treatment protocol which stimulates peripheral venous blood flow may help to alleviate harmful venous pressures in venous leg ulcer patients and provide some degree of strengthening of the calf muscles, thus helping to accelerate the healing rates of venous ulcers.

Eligibility criteria:
inclusion criteria: * primary or recurrent venous leg ulcer. * ankle-brachial pressure index \> 0.8 * ulcer size between 1 and 200 cm2 * patient suitable for full compression bandaging exclusion criteria: * history of symptomatic heart disease. * pregnancy * presence of implants in the lower leg or a pacemaker * history of a neurological disorder * presence of any contraindications for the use of compression stockings such as severe arterial disease i.e. ankle brachial pressure index (abpi) \<0.8 * presence of cognitive difficulties which may prevent the patient or his/her carer from using the stimulator appropriately. * patients unable to provide informed consent * patients receiving dialysis * patients receiving steroids * patients receiving methotrexate * ulcer located in the area of electrode placement * patients in reduced compression bandaging system

Keywords: venous ulceration leg ulcers venous haemodynamics surface neuromuscular electrical stimulation snmes
efficient anterior shoulder ultrasound reduction multicenter prospective randomized trial

Conditions: Shoulder Dislocation

Summary: the purpose of the study is to determine if using ultrasound to diagnosis and confirm reductions of shoulder dislocations impacts the length of an emergency department visit for this condition.

the purpose of the study is to determine if the length of the emergency department visit can be decreased and if patient exposure to x-rays can be reduced by utilizing an ultrasound to diagnose and confirm reduction in shoulder dislocations. this study also seeks to determine if patients prefer ultrasound to x-ray when used to treat their shoulder dislocation. participants will be randomly assigned to one of two groups: either x-rays or ultrasound for the diagnosis and reduction confirmation of your shoulder dislocation. participant's shoulder dislocation will be treated per standard of care. participants will be asked to complete a short survey at the end of their visit.

Eligibility criteria:
inclusion criteria: 1. patients who are 18 years of age or older; and 2. present to the vcu emergency department; and 3. have clinical signs of uncomplicated shoulder dislocation; and 4. agree to participation in the study; and 5. provides a written consent to be included in the study. exclusion criteria: 1. patients who have a level 1 or 2 trauma activation, and/or; 2. patients who are pregnant, incarcerated, or unable to consent, and/or; 3. patients who have a past medical history of shoulder replacement in dislocated shoulder; and/or 4. provider discretion
deep rtms (h-coil) for neuropathic pain or fibromyalgia

Conditions: Neuropathic Pain; Fibromyalgia

Summary: this study will investigate the efficacy and safety of "deep" rtms on neuropathic pain or fibromyalgia. it will be randomized and sham controlled and will last 3 months. patients will be randomized to receive acctive rtms or sham rtms and will receive repeated rtms sessions (5 daily sessions then one session per week then every 2 to 3 weeks for up to 10 weeks).

this double blind sham controlled parallel group bicenter study will assess the efficacy and safety of repeated sessions of deep rtms using h coil in patients with neuropathic pain or fibromyalgia. primary outcome will be % of pain relief at week 13.

Eligibility criteria:
inclusion criteria: * chronic pain ≥ 6 months, at least 4/10 on a 0-10 nrs, present every day or nearly every day * neuropathic pain (confirmed with douleur neuropathique en 4 questions and international criteria from neupsig) or fibromyalgia (revised acr criteria) * stable concomitant medications for pain for at least one month * able to fill out questionnaires and understand and speak french exclusion criteria: * contraindications to rtms * prior treatment with rtms * progressive severe condition (eg cancer) * psychosis * psychoactive drug abuse
comparison of several oxygenation targets with different oxygen interfaces - impact on oxygen flow rates

Conditions: Oxygen Toxicity; COPD Bronchitis; Respiratory Failure

Summary: oxygen therapy is at the heart of the healthcare system. oxygen flow rates depend on a number of confounding factors confounding factors (target used, skin pigmentation, pulse oximeter used, etc.) the investigators have recently have recently demonstrated that the combination of these factors (different peripheral oxygen saturation (spo2) targets and different oximeters) can have a significant impact on oxygen flows rates. the effect on oxygen flow was not simply additive . the aim of this study is to evaluate the impact of the interface used on oxygen flow rates in different patient populations (main objective). the investigatoers also evaluate the impact of the interface on carbon dioxide (paco2), in particular with closed oxygen masks, with which rebreathing is theoretically possible (secondary objective). secondary objective).


Eligibility criteria:
inclusion criteria: * adult (\> or = 18 years old) * ongoing on conventional oxygen therapy with peripheral oxygen saturation (spo2) between 88 and 100% with the usual oximeter * spo2 \< 92% ambient air with the usual oximeter exclusion criteria: * no spo2 signal with with the usual oximeter * false nails or nail polish * severe anemia documented on last blood count during current hospitalization (haemoglobin (hb) \< 80g/l) * oxygen flow \> 6 l/min
expiratory flow limitation and postoperative complications

Conditions: Postoperative Respiratory Complications

Summary: expiratory flow limitation (efl) occurs when flow ceases to increase with increasing expiratory effort. in any circumstances efl predisposes to pulmonary dynamic hyperinflation and its unfavorable effects such as increased elastic work of breathing, inspiratory muscles dysfunction, and progressive neuroventilatory dissociation, leading to reduced exercise tolerance, marked breathlessness during effort, and severe chronic dyspnea. our hypothesis is that efl should affect post operative outcomes like incidence of pulmonary complication and length of stay in hospital


Eligibility criteria:
inclusion criteria: * general anesthesia * duration of the surgery \>2 hours exclusion criteria: * \<18 years * consensus not given
safety and efficacy of bkm120 in patients with metastatic non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this two-stage phase ii study is to assess the efficacy of bkm120, as measured by determining the progression free survival (pfs), in patients with pretreated metastatic non-small cell lung cancer (nsclc) that exhibits pi3k pathway activation. bkm120 will be investigated in two groups of nsclc patients according to the histology of the cancer: squamous and non-squamous.


Eligibility criteria:
inclusion criteria: * histologically confirmed nsclc with activated pi3k pathway * progressive disease after prior systemic antineoplastic treatment(s) for advanced nsclc * archival or fresh tumor biopsy must be available for profiling * measurable and/or non-measurable disease as per recist 1.1 criteria * eastern cooperative oncology group (ecog) performance status ≤ 2 * adequate organ function as assessed by laboratory tests exclusion criteria: * patient has received previous treatment with pi3k inhibitors * patient with squamous nsclc has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous nsclc has received more than two lines of systemic antineoplastic treatment for metastatic disease * uncontrolled or symptomatic cns metastases * concurrent use of any other approved or investigational antineoplastic agent * radiotherapy ≤ 28 days prior to starting study drug * major surgery within 28 days prior to starting study drug * history of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus * current treatment with medication that has a known risk to prolong the qt interval or inducing torsades de pointes * impairment of gastrointestinal (gi) function * chronic treatment with steroids or another immunosuppressive agent. * concurrent severe and/or uncontrolled medical condition * currently receiving warfarin or another coumarin derivative * known history of hiv infection * sensory neuropathy with functional impairment (ctc grade 2 neuropathy, regardless of causality) * pregnancy, lactation, or breastfeeding * woman of child-bearing potential other protocol-defined inclusion/exclusion criteria may apply

Keywords: nsclc pi3k
cyclooxygenase-2 inhibitor for adjuvant anticancer effect in patients with biliary-pancreas cancer

Conditions: Bile Duct Cancer; Pancreatic Cancer

Summary: in extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with cox2 inhibitor and assess survival rate and recurrent rate.

patients : total 220 patients * extrahepatic bile duct cancer : 55 patients for administration of cox2 55 patients for control group * pancreas cancer : 55 patients for administration of cox2 55 patients for control group indication * after operation of extrahepatic bile duct cancer or pancreas cancer * age : 19 - 70 years old * the patients who agree to consent sheet. contraindication * impossible of administration due to severe postoperative morbidities (bleeding, bowel obstruction, pancreatic fistula, biliary fistula) * preexisting heart disease: ischemic heart disease, heart failure. severe uncontrolled hypertension (systolic bp\>160) * renal insufficiency: ccr \ 3.0 * hepatic insufficiency: liver cirrhosis or active hepatitis * preexisting allergic reaction history for nsaids or sulfonamide * current drug intake: warfarin. lithium, fluconazole, aspirin, celecoxib * preexisting asthma. especially aspirin-sensitive asthma. * contraindications to aspirin, clopidogrel or celecoxib * the patients who refuse trial * the patients who has psychogenic problem allocation * we will allocate patients randomly, to administration group or control group methods * from postoperative third day, administration will be started * celecoxib 200mg bid for 6 months for administration group * follow up and assess recurrence rate and survival rate

Eligibility criteria:
inclusion criteria: * the patients who underwent operation for extrahepatic bile duct cancer or pancreas cancer * between 19 and 70 years old * agreed to consent sheet exclusion criteria: * the patients cannot administration of drug due to severe postoperative morbidities. * preexisting heart disease: ischemic heart disease, heart failure. severe uncontrolled hypertension (systolic bp\>160) * renal insufficiency: ccr \ 3.0 * hepatic insufficiency: liver cirrhosis or active hepatitis * preexisting allergic reaction history for nsaids or sulfonamide * current drug intake: warfarin. lithium, fluconazole, aspirin, celecoxib * preexisting asthma. especially aspirin-sensitive asthma. * contraindications to aspirin, clopidogrel or celecoxib * when patients refused * patients has psychological problem

Keywords: cyclooxygenase-2 inhibitor (celecoxib) extrahepatic bile duct cancer pancreas cancer
acetaminophen in combination with n-acetylcysteine (nac) versus placebo in treating fever

Conditions: Liver Failure; Liver Failure, Acute; Drug Induced Liver Injury; Prevention & Control; Fever

Summary: the purpose of this study is to compare the efficacy of the an n-acetyl-p-aminophenol (apap, also known as acetaminophen) and n-acetylcysteine (nac) combination versus an apap-placebo combination as an anti-pyretic agent.

n-acetyl-p-aminophenol (apap), or more commonly known as acetaminophen in the united states, accounts for more overdose and overdose deaths in the united states and united kingdom than any other pharmaceutical agent. if n-acetylcysteine (nac) is given within 8 to 10 hours of apap ingestion, it has been shown to prevent serious liver failure and death in the setting of overdoses. therefore, it may be beneficial to administer apap in combination with nac routinely to reduce rates of liver failure and death. because nac's main role is to reduce the accumulation of apap's toxic metabolites, the concomitant administration of nac should have no impact on the efficacy of apap as an antipyretic and analgesic. thus, we propose a single-center, non-inferiority randomized control study comparing the efficacy of the apap-nac combination as compared to apap-placebo as an anti-pyretic agent.

Eligibility criteria:
inclusion criteria: * adults aged 18 to 75 years old * admitted to an inpatient unit at columbia-presbyterian medical center * fever defined as an oral temperature of 38.5°c exclusion criteria: * if oral temperature cannot be obtained * abnormal aminotransferase levels * prior adverse reaction to acetaminophen or n-acetylcysteine

Keywords: acetaminophen acetylcysteine antidotes
evaluation of serum pentraxin 3 and high sensitive crp in female patients with gestational diabetes mellitus in second trimester of pregnancy

Conditions: Gestational Diabetes Mellitus in Second Trimester of Pregnancy

Summary: 1. to assess the value of serum pentraxin-3 and high sensitive crp in females with normal pregnancy and females with gestational diabetes mellitus in second trimester of pregnancy. 2. to study correlations between serum pentraxin-3 and high sensitive crp in gestational diabetes.

gestational diabetes mellitus (gdm) refers to abnormal glucose metabolism that occurs or is discovered during pregnancy, it can cause multiple poor outcomes and increase maternal and child prevalence and mortality. gdm can increase the risk of type 2 diabetes mellitus (t2dm) and cardiovascular diseases in pregnant women, and the risk of metabolic disorders in their offspring is high, so it's called a disease that affects two generations.(1) the relationship between maternal hyperglycemia and fetal macrosomia together with other complications has been confirmed.(2) women with gdm have a higher long-term risk of type 2 diabetes mellitus.(3) pentraxin 3 (ptx3) and high sensitive crp are both the acute phase proteins belonging to the pentraxin family but with different biological characteristics, crp belongs to the short ptx, which is an acute phase protein synthesized by the hepatocytes when the body is stimulated by microbial invasion or tissue damage.(4) ptx3 is a long-chain ptx protein. a variety of tissue cells can produce ptx3 under the stimulation of pro-inflammatory factors, including the endothelial cells, fibroblasts, monocytes, adipocytes, etc.(5,6) there is one study(changes of serum pentraxin-3 and hypersensitive crp levels during pregnancy and their relationship with gestational diabetes mellitus , 2019) , that has come to ptx3 and hs-crp may be related to the pathogenesis of gdm, and they are significantly increased in the second trimester, which provides a new idea for early prevention and treatment of gdm .

Eligibility criteria:
inclusion criteria: 1. pregnant women. 2. diagnosed gdm. 3gestational age \>20weeks exclusion criteria: 1. women with pregestational diabetes . 2. women with chronic diseases. 3. twin pregnancy.

Keywords: serum pentraxin 3,high sensitive crp in female patients with gestational diabetes mellitus
intraop ventilation management and postop pulmonary complications in high risk patients for osa

Conditions: Ventilator-Induced Lung Injury

Summary: lung protective ventilation (lpv) has been proposed to reduce the incidence of postoperative pulmonary complications (ppcs), and protect against ventilator induced lung injury (vili).

lpv was first introduced in the intensive care units but has been recently adopted in the operating rooms. obstructive sleep apnea (osa) is a widely prevalent condition in obese patients and requires special attention in the operating room. screening for osa risk in surgical patients is a common practice. the stop-bang questionnaire is a common screening tool for osa (snoring, tiredness, observed apnea, high blood pressure, bmi, age, neck circumference, and male gender). the american society of anesthesiologists practice guidelines for the perioperative management of patients with osa do not recommend any specific ventilation strategy to prevent ppcs in this population. to the knowledge of the investigators, the association between intraoperative ventilation strategies and ppcs in laparoscopic bariatric surgery patients, who have a high stop-bang score, has not been adequately investigated. the investigators propose a retrospective chart review of patients, 18 years of age and older, who underwent laparoscopic bariatric surgery, in reverse trendelenburg position, using pressure controlled ventilation (pcv/pcv-vg) at the ohio state university wexner medical center, between january 01, 2012 and november 22, 2016, to determine whether intraoperative driving pressure is a predictor of postoperative pulmonary complications. no procedures will be done for the sake of conducting this study except for a retrospective review of patient charts. preoperative and intraoperative variables will be collected to determine their predictive value of postoperative complications. no risks to the patients' health or well being are anticipated due to the conduct of the proposed study. no immediate benefits to the patients from whom data was collected is anticipated either. results obtained from this study may provide valuable information on the preferred ventilation strategies in the operating room for future patients who have a high risk of postoperative lung complications.

Eligibility criteria:
inclusion criteria: * male or female * age ≥ 18 y/o * patients who underwent laparoscopic bariatric surgery * surgery under general anesthesia with endotracheal intubation and pressure controlled mode of ventilation (pcv or pcv-vg) exclusion criteria: * pregnant females, prisoners * short procedures: time of mechanical ventilation \< 60 minutes * patients who received volume controlled ventilation (vcv) mode * patients with past medical history of neuromuscular illnesses, pulmonary hypertension or chf
variations of immune infiltrate and cell plasticity markers in treated metastatic melanoma patients

Conditions: Melanoma

Summary: coleman is an opened prospective monocentric non-randomized study, initiated by the hospices civils de lyon. population targeted are patients from 18 years old with stage iii or iv metastatic melanoma eligible for a metastatic melanoma treatment administered as part of usual care. the objective is to study the variations of immune infiltrate and cell plasticity before and under immunotherapy or targeted therapy. two biopsies are done before and one month after the treatment initiation and one blood sample is done after the treatment initiation. 100 patients will be included and followed during 5 years.


Eligibility criteria:
inclusion criteria: * patient age ≥ 18 * female patients must agree to the use of 2 methods of contraception. for man one method of contraception is needed if if his partner is in childbearing age throughout the study and for at least 5 months after last study treatment administration. * patients with metastatic stage iii or iv melanoma relapse * eligible for a melanoma metastatic treatment indicated and administered as part of usual care * patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol * patient insured or beneficiary of a health insurance plan * patient able to provide informed consent and sign approved consent forms to participate in the study * patient accepting the conservation of biological samples and their use for clinical research including genetic research exclusion criteria: * hematologic tumours under treatment * patients with a documented history of autoimmune pathology * ocular melanoma * persons placed under the safeguard of justice * use of immunosuppressants including corticosteroids 4 weeks before the inclusion

Keywords: melanoma immune infiltrate cell plasticity markers